Viking Therapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGViking Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 35), showing significant lag compared to the market leaders. Earnings contraction of 234% provides fundamental context to the price action. Investors should exercise caution due to high volatility (74% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $33.41 | -3.39% | BELOW |
| 50 SMA | $33.46 | -3.51% | BELOW |
| 100 SMA | $33.01 | -2.21% | BELOW |
| 150 SMA | $33.77 | -4.41% | BELOW |
| 200 SMA | $32.76 | -1.46% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is VKTX in an uptrend right now?
VKTX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is VKTX overbought or oversold?
VKTX's RSI (14) is 42. The stock is in neutral territory, neither overbought nor oversold.
Is VKTX outperforming the market?
VKTX has a Relative Strength (RS) Rating of 35 out of 99. VKTX is currently lagging the broader market.
Where is VKTX in its 52-week range?
VKTX is trading at $32.28, which is 75% of its 52-week high ($43.15) and 46% above its 52-week low ($22.96).
How volatile is VKTX?
VKTX has a Beta of 1.61 and 52-week volatility of 74%. It's more volatile than the S&P 500 - expect bigger swings.